Physician profile
Arunava Ray
NPI 1568465094
$7,903.21
in general payments reported to CMS, 2019-2025
24 companies · $2,069 in 2025
The $2,069 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $50.69 · 2021: $42.91 · 2022: $207 · 2023: $2,794 · 2024: $2,235 · 2025: $2,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,665 · Travel and Lodging: $3,414 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,665.04 |
| Travel and Lodging | $3,414.03 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,812.64 | 2020-2025 | Varithena Administration Pack, Watchman Flx, Ekosonic |
| Abbott Laboratories | $1,756.00 | 2019-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Jeti All In One Non-Sterile Kit |
| E.R. Squibb & Sons, L.L.C. | $701.28 | 2022-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $459.24 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $385.40 | 2022-2025 | Verquvo, Winrevair, Capvaxive |
| Amgen INC. | $326.45 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $249.51 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $213.69 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $194.53 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.20 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $120.86 | 2023-2025 | Wegovy, Ozempic |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.58 | 2022-2023 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $92.91 | 2024-2025 | |
| Abiomed | $55.26 | 2024-2025 | Impella |
| Ge Healthcare | $42.91 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $38.27 | 2025 | Reveal Linq, Turbohawk |
| Lexicon Pharmaceuticals, INC. | $29.82 | 2024 | |
| Astellas Pharma US INC | $23.43 | 2019 | |
| Daiichi Sankyo INC. | $21.63 | 2025 | Injectafer |
| Angiodynamics, INC. | $20.19 | 2023 | Venacure 1470 Pro |
| Sanofi-Aventis U.S. LLC | $19.68 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.99 | 2025 | Amvuttra |
| Gilead Sciences, INC. | $17.08 | 2019 | |
| Itamar Medical INC | $4.66 | 2024 | Watchpatone |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arunava Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.